Clinical Trial Detail

NCT ID NCT02744612
Title Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors City of Hope Medical Center
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin + Ibrutinib

Age Groups: adult child

No variant requirements are available.